The novel selective pan-TRK inhibitor ONO-7579 exhibits antitumor efficacy against human gallbladder cancer in vitro

Biochemistry, Genetics and Molecular Biology

• Brain-Derived Neurotrophic Factor 20%
• Cancer Cell 20%
• Clinical Trial 40%
• Electric Potential 20%
• KRAS 20%
• Mutant 20%
• Phase I Trials 40%
• Phenotype 20%
• Receptor Tyrosine Kinase 20%
• Solid 20%
• Tyrosine Kinase 2 20%
• Vascular Endothelial Growth Factor 20%

Immunology and Microbiology

• Brain Derived Neurotrophic Factor 20%
• Cancer Cell 20%
• Electric Potential 20%
• Gallbladder 100%
• Mutant 20%
• Phenotype 20%
• Solid 20%
• Vasculotropin 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Brain Derived Neurotrophic Factor 20%
• Brain Derived Neurotrophic Factor Receptor 20%
• Cefaclor 20%
• Gallbladder Cancer 100%
• Malignant Neoplasm 20%
• Solid Malignant Neoplasm 20%
• Vasculotropin 20%